Belite Bio Inc.

09/10/2024 | Press release | Distributed by Public on 09/10/2024 06:22

Belite Bio Announces First Patient Dosed in Phase 2/3 DRAGON II Trial of Tinlarebant for the Treatment of Stargardt Disease